Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Inv. presentation
SALIX PHARMACEUTICALS LTD (SLXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/30/2011 BW Salix Pharmaceuticals to Present at Three Investment Conferences in June
05/20/2011 BW Salix Pharmaceuticals Reviews Data Presentations at American Pain Society Annual Meeting
05/05/2011 BW Salix Pharmaceuticals Reports 1Q2011 Results
04/25/2011 BW Salix Pharmaceuticals to Present at Two Investment Conferences in May
04/21/2011 BW Salix Pharmaceuticals Announces 1Q2011 Financial Results Conference Call and Webcast
04/20/2011 BW Salix Pharmaceuticals Secures Additional Intellectual Property Relating to Rifaximin
04/06/2011 BW Salix Pharmaceuticals Expands Rifaximin Collaboration with Lupin
04/04/2011 BW Salix Reviews the International Liver Congress 2011 Of the European Association for the Study of the Liver
03/08/2011 BW Salix Receives Anticipated FDA Complete Response Letter On XIFAXAN® 550 Mg Tablets Non-C IBS Supplemental New Drug Application
02/28/2011 BW Salix Pharmaceuticals Reports 4Q2010 and FY2010 Results
02/24/2011 BW Salix Anticipates Receipt of FDA Complete Response Letter on XIFAXAN® 550 Mg Tablets Supplemental New Drug Application
02/23/2011 BW Salix To Host Conference Call to Provide Update Regarding FDA Review Of XIFAXAN® 550 MG Tablets Supplemental New Drug Application
02/23/2011 BW Salix Pharmaceuticals to Present at Three Investment Conferences in March
02/14/2011 BW Salix Pharmaceuticals Announces 4Q2010 and FY2010 Financial Results Conference Call and Webcast
11/23/2010 BW Salix Pharmaceuticals to Present at Piper Jaffray Conference
11/08/2010 BW Salix Pharmaceuticals Reports 3Q2010 Results
11/03/2010 BW Salix Pharmaceuticals to Present at Credit Suisse Conference
10/30/2010 BW Salix Pharmaceuticals Previews Data Slated for Presentation at 61st Annual Meeting of the American Association for the Study of Liver Diseases
10/20/2010 BW Salix Pharmaceuticals Acquires Lumacan™ from Photocure
10/20/2010 BW Salix Pharmaceuticals Acquires Lumacan™ from Photocure
10/18/2010 BW XIFAXAN 550 mg (Rifaximin) Demonstrates Acute and Sustained Relief of Non-Constipation Irritable Bowel Syndrome Symptoms: Data Presented at the 2010 American College of Gastroenterology (ACG) Annual Meeting
09/29/2010 BW Salix Pharmaceuticals to Present at Jefferies Conference
09/21/2010 BW Salix Pharmaceuticals to Present at JMP Conference
09/09/2010 BW Salix Pharmaceuticals to Present at Stifel Nicolaus Conference
08/30/2010 BW Salix Pharmaceuticals Announces Settlement of Pending Litigation Regarding MOVIPREP®
08/09/2010 BW Salix Pharmaceuticals Reports 2Q2010 Results
08/09/2010 BW Salix Announces FDA Acceptance for Filing and Priority Review Designation For XIFAXAN550 sNDA For the Treatment of Non-Constipation Irritable Bowel Syndrome
07/29/2010 BW Salix Pharmaceuticals to Present at BMO Capital Markets Conference
06/16/2010 BW Salix Pharmaceuticals to Present At NASDAQ Conference
05/03/2010 BW XIFAXAN 550 mg (rifaximin) Demonstrated Acute and Sustained Relief of Non-Constipation Irritable Bowel Syndrome Symptoms; Data from Target 1&2 Presented at Digestive Disease Week (DDW)
04/28/2010 BW FDA Issues Communication Regarding GIAZO™ New Drug Application
04/27/2010 BW H.E.L.P. is on the Way for Patients with Hepatic Encephalopathy (HE)
04/26/2010 BW Salix Pharmaceuticals Announces 1Q2010 Financial Results Conference Call and Webcast
04/21/2010 BW Salix Pharmaceuticals to Host DDW2010 Investor Event on May 3
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy